A Systematic Review on the Role of FDG-PET/CT in Tumour Delineation and Radiotherapy Planning in Patients with Esophageal Cancer
Overview
Authors
Affiliations
Purpose: FDG-PET/CT has proven to be useful in the staging process of esophageal tumours. This review analysed the role of FDG-PET/CT in tumour delineation and radiotherapy planning in comparison with CT alone among patients with esophageal cancer. Thereby we focused on the detection of the primary tumour and lymph nodes by FDG-PET/CT, changes in target volume (TV) delineation based on FDG-PET/CT and its validity, changes in inter- and intra-observer variability in TV delineation, consequences for radiotherapy treatment planning with regard to either target volumes or organs at risk and finally on the validation of FDG-PET/CT-based TVs in terms of treatment outcome.
Methods: A literature search was performed in MEDLINE and Cochrane library databases for studies concerning the current value of FDG-PET/CT in tumour detection and delineation and radiotherapy-planning procedures among patients with esophageal cancer. Both prospective and retrospective studies were included.
Results: Fifty publications met the eligibility criteria, of which 19 were review papers and one was a case report. The remaining 30 publications reported on the results of original studies. FDG-PET was able to identify most primary tumours, with a sensitivity and specificity for the detection of metastatic lymph nodes of 30-93% and 79-100%. The use of FDG-PET/CT resulted in changes of target volumes, and consequently in changes in treatment planning. However, evidence supporting the validity of the use of FDG-PET/CT in the tumour delineation process is very limited. Only three studies reported a significant positive correlation between FDG-PET-based tumour lengths and pathological findings. There were two studies that tested the influence of FDG-PET/CT to the inter- and intra-observer variability. One of them found a significant decrease in inter- and intra-observer variability, while the others did not. Furthermore, there are no studies demonstrating the use of PET/CT in terms of improved locoregional control or survival.
Conclusion: Since the literature is very limited standard implementation of FDG-PET/CT into the tumour delineation process for radiation treatment seems unjustified and needs further clinical validation first.
Zeng Y, Liu Y, Li J, Feng B, Lu J Ann Surg Oncol. 2024; 32(3):1635-1650.
PMID: 39586955 DOI: 10.1245/s10434-024-16568-z.
Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature.
Mehta A, Vadgaonkar R, Lewis S, Mahantshetty U, Agarwal J Rep Pract Oncol Radiother. 2024; 29(3):391-408.
PMID: 39144270 PMC: 11321780. DOI: 10.5603/rpor.100777.
Esophageal cancer - the utility of PET/CT in staging prior to chemoradiation.
Deja A, Wlodarczyk M Rep Pract Oncol Radiother. 2024; 28(5):608-611.
PMID: 38179288 PMC: 10764044. DOI: 10.5603/rpor.96869.
Ha L, Chau N, Bieu B, Son M World J Nucl Med. 2023; 22(3):226-233.
PMID: 37854080 PMC: 10581756. DOI: 10.1055/s-0043-1774417.
Li F, Li Y, Wang X, Zhang Y, Liu X, Liu S Front Oncol. 2022; 12:817413.
PMID: 35433413 PMC: 9010659. DOI: 10.3389/fonc.2022.817413.